|Webcasts|October 29, 2019

Will Decentralized Clinical Trials Compound Patient and Data Quality Risks?

Recent research has emboldened the industry as it moves from traditional to hybrid studies with the promise of greater patient participation and patient access – despite this risk to overall study quality data was cited as the number one concern with decentralized trials. How can these risks be mitigated against? Live: Tuesday, Oct. 29, 2019 at 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Oct. 29, 2020. Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/dcts

Event Overview:
Decentralized Clinical Trials (DCTs) offer a more patient-centric approach in which fewer clinic visits are required and patient and caregiver burden are reduced. DCTs utilize a wide range of digital technologies to collect safety and efficacy data from study participants, normally remotely from the patient’s own home.

With the introduction of a DCT, a significant element of patient engagement is moved away from a controlled (physical) investigator and site environment, which will present significant patient and data quality risks. Additional burdens incurred by adopting this technical infrastructure include, but at not limited to; system validation, creation of patient application training materials and patient training, and study setup and configuration prior to activation/enrollment.

This webcast will focus on understanding these risks and how they can be mitigated.

Key Learning Objectives:

In this webcast we will explore:

The perceived impact of DCTs on investigative sites, studies, staff roles and patients

The perceived benefits of DCTs on conducting studies, including additional burdens inherent in this new technical infrastructure

The challenges cited to DCTs in terms of adoption by the industry

The additional quality management elements required to mitigate patient and data quality risks resulting from DCTs

The future of DCTs and the reality facing stakeholders continuing to conduct clinical trials in an industry embracing technology

Time and date: Tuesday, Oct. 29, 2019 at 1pm EDT | 12pm CDT | 10am PDT

On demand available after airing until Oct. 29, 2020.

Sponsor: Oracle Health Sciences

Register free: http://www.appliedclinicaltrialsonline.com/act_w/dcts


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.